Insider Selling: Steven Robert Pacelli Sells 14,000 Shares of DexCom Stock (DXCM)
DexCom (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 14,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.24, for a total transaction of $619,360.00. Following the sale, the executive vice president now directly owns 241,399 shares of the company’s stock, valued at approximately $10,679,492. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company. DexCom currently has a consensus rating of “Hold” and a consensus price target of $41.00.
Shares of DexCom (NASDAQ:DXCM) traded down 1.55% on Wednesday, hitting $45.18. 663,270 shares of the company’s stock traded hands. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock’s 50-day moving average is $40.3 and its 200-day moving average is $39.08. The company’s market cap is $3.410 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.